Tg Therapeutics (TGTX) Cash from Operations (2011 - 2026)

Tg Therapeutics' Cash from Operations history runs 16 years deep, the most recent figure standing at 17894000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 37.68% year-over-year to 17894000.0 in Q1 2026; TTM through Mar 2026 was 13951000.0, a 77.14% increase from a year earlier, with the FY2025 full-year figure at 24772000.0, up 38.86% from the prior year.
• Cash from Operations declined to 17894000.0 in Q1 2026 per TGTX's latest filing, from 19660000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 83704000.0 in Q3 2023 and bottomed at 68689000.0 in Q1 2022.
• The 5-year median for Cash from Operations is 23153000.0 (2025), against an average of 17103882.35.
• Across the five-year window, Cash from Operations surged 342.66% in 2023 and plunged 249.88% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 23870000.0 in 2022, then surged by 44.66% to 13210000.0 in 2023, then plunged by 94.1% to 25641000.0 in 2024, then jumped by 176.67% to 19660000.0 in 2025, then plunged by 191.02% to 17894000.0 in 2026.
• Per Business Quant, the three latest TGTX Cash from Operations figures stand at 17894000.0 (Q1 2026), 19660000.0 (Q4 2025), and 23153000.0 (Q3 2025).